Avenue Therapeutics

Biotechnology ResearchNew York, United States2-10 Employees

Avenue Therapeutics, Inc. is a biotechnology research company focused on the development and commercialization of therapies for rare and neurologic diseases, and it operates as a Fortress Biotech subsidiary. The company is based in New York, at 2 Gansevoort Street, 9th Floor, New York, NY 10014, United States, and employs a small team of 2 to 10 people. Avenue Therapeutics has pursued development of ATX-04 (clenbuterol) for Pompe disease and has secured an exclusive worldwide license with Duke University for patents and know-how related to this compound in clinical development. Its activities include other drug development programs and corporate actions, such as the GABA-A receptor potentiator BAER-101, an intravenous tramadol program for acute postoperative pain with FDA study-design coordination, and corporate actions including the acquisition of Baergic Bio and exclusive license for AJ201 to treat SBMA. The company is publicly traded on the OTC market under the ticker ATXI and has reported modest revenue and funding levels.

Sign up for free to view info

Email Format Employee directory